Marshall Islands vs Sao Tome and Principe: Hepatitis B surface antigen (HBsAg) prevalence
Marshall Islands
0.9%
in 2024
Sao Tome and Principe
0.8%
in 2024
Marshall Islands rank
36th
Sao Tome and Principe rank
39th
Hepatitis B surface antigen (HBsAg) prevalence over time
- Marshall Islands
- Sao Tome and Principe
How they compare
Marshall Islands currently reports 0.9% against 0.8% in Sao Tome and Principe, a difference of 0.1%.
That makes Marshall Islands's figure about 1.1 times Sao Tome and Principe's.
Across all 10 years both countries report, Marshall Islands has been ahead every year.
Marshall Islands ranks 36th and Sao Tome and Principe ranks 39th of 194 countries.
Marshall Islands has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Marshall Islands | Sao Tome and Principe | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.4% | 0.9% | 0.4% | Marshall Islands |
| 2020s | 1.0% | 0.8% | 0.2% | Marshall Islands |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Marshall Islands or Sao Tome and Principe?
- Marshall Islands, at 0.9% against 0.8% in Sao Tome and Principe as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Marshall Islands and Sao Tome and Principe?
- 0.1%, with Marshall Islands ahead.
- How many years of comparable data are there for Marshall Islands and Sao Tome and Principe?
- 10 years are reported by both, from 2015 to 2024.
- How do Marshall Islands and Sao Tome and Principe rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Marshall Islands ranks 36th and Sao Tome and Principe ranks 39th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.